Core Viewpoint - The announcement of a purchase limit for the NuAn Multi-Strategy Mixed Fund indicates a strategic shift in response to its strong performance, particularly driven by small-cap stocks under the management of Kong Xianzheng [2][3]. Group 1: Fund Performance - As of July 9, 2025, the A-class shares of the NuAn Multi-Strategy Mixed Fund have seen a year-to-date net value increase of 44.72%, ranking 60th among peers, and a one-year cumulative return of 112.07%, ranking 14th [2]. - The fund's performance has been significantly influenced by its heavy investment in small-cap stocks, with all top ten holdings having market capitalizations below 5 billion yuan, the highest being 3.6 billion yuan for Bangji Technology [2]. - Under Kong Xianzheng's management, the fund's turnover rate reached 10 times in the first half of 2023, with individual stock holdings being closely balanced, indicating a diversified approach [3]. Group 2: Management Changes - Kong Xianzheng's appointment in February 2023 marked a significant change in the fund's investment strategy, shifting focus from sectors like pharmaceuticals and banking to small-cap stocks [2][3]. - The fund's performance in the third and fourth quarters of 2023 showed net value increases of 10.65% and 8.06%, respectively, while many other products experienced declines [3]. Group 3: Comparison with Other Funds - The NuAn Multi-Strategy Mixed Fund A has achieved a cumulative return of 57.00% during Kong Xianzheng's tenure, with a six-month net value growth of 48.17%, placing it in the top 2% of its category [5]. - In contrast, the NuAn Selected Value Mixed Fund, managed by Tang Chen, outperformed the NuAn Multi-Strategy Mixed Fund by over 20 percentage points in the last six months, driven by a focus on innovative drug companies [5][6]. Group 4: Market Insights - Tang Chen highlighted that the innovative drug sector is entering a phase of value realization, with many products expected to complete negotiations for medical insurance inclusion between 2024 and 2025, which will drive revenue growth [6]. - The current market environment suggests a re-evaluation of the value of research pipelines, with some companies expected to reach breakeven by 2026, indicating a clear growth momentum [6].

Core Viewpoint - The performance of funds in the first half of the year has been significantly influenced by the strong rally in Hong Kong's innovative pharmaceutical sector, with the top-performing fund, Huatai-PineBridge Hong Kong Advantage Selection, achieving over 85% returns [1][3]. Fund Performance - As of June 30, 2023, the top-performing fund, Huatai-PineBridge Hong Kong Advantage Selection, recorded a return of 86.00% [2][3]. - Other notable funds include CITIC Construction Investment North Exchange Selection and Great Wall Pharmaceutical Industry Selection, with returns of 82.45% and 75.18% respectively [6]. - The overall performance of the Hong Kong stock market, particularly in the innovative pharmaceutical sector, has been robust, with the Hang Seng Index and Hang Seng Technology Index rising by 20% and 18.68% respectively [3]. Market Trends - The innovative pharmaceutical sector in Hong Kong has been a key driver of fund performance, with many funds heavily invested in this area [4][6]. - The Hang Seng Hong Kong Innovative Pharmaceutical Selection Index has seen a year-to-date increase of 58.95%, indicating strong market interest and growth potential [6][7]. - Analysts predict that the innovative pharmaceutical sector will continue to benefit from policy support and market dynamics, suggesting a favorable outlook for the second half of the year [7][8]. Investment Insights - Fund managers believe that the pharmaceutical industry will experience a recovery in growth due to normalized regulations and increasing domestic medical demand [3][4]. - The current market environment is characterized by a combination of policy benefits, global liquidity, and positive market sentiment, which are expected to sustain the growth of innovative pharmaceutical companies [7][8]. - The disparity in fund performance highlights the importance of strategic investment choices, with some funds underperforming despite being in popular sectors [9].

Core Viewpoint - The article provides a ranking of open-end funds based on their net asset value growth, highlighting the top and bottom performers in the market [2][4][6]. Fund Performance Summary - The top 10 funds with the highest net value growth as of May 6, 2025, include: 1. 德邦鑫星价值A (1.4682) 2. 德邦鑫星价值C (1.4119) 3. 永赢数字经济智选混合发起C (1.0368) 4. 永赢数字经济智选混合发起A (1.0452) 5. 信澳匠心回报混合A (1.3803) 6. 信澳匠心回报混合C (1.3669) 7. 易方达先锋成长混合C (0.9778) 8. 易方达先锋成长混合A (0.9921) 9. 易方达瑞享混合I (2.8476) 10. 易方达瑞享混合E (2.3079) [2][4]. - The bottom 10 funds with the lowest net value growth include: 1. 中航优选领航混合发起C (1.3939) 2. 中航优选领航混合发起A (1.3971) 3. 创金合信医疗保健股票C (1.6551) 4. 创金合信医疗保健股票A (1.7250) 5. 诺安精选价值混合 (1.4247) 6. 诺安精选价值混合C (1.4177) 7. 长城医药产业精选混合发起式A (1.4219) 8. 中银证券健康产业混合 (2.0409) 9. 长城医药产业精选混合发起式C (1.4181) 10. 富国精准医疗灵活配置混合C (2.7876) [4][6]. Market Analysis - The Shanghai Composite Index opened high and showed a single upward trend, closing with a small gain, while the ChiNext Index also rebounded after initial fluctuations, indicating a positive market sentiment with a total transaction volume of 1.36 trillion [6]. - Leading sectors included mineral products, software services, and communication equipment, all showing gains of over 3%, while banking and oil sectors lagged behind [6]. Fund Holdings Overview - The top holdings of the funds with significant net value growth include companies in the technology and communication sectors, with a notable concentration in the top ten holdings, which accounted for 57.94% of the total holdings [7]. - Conversely, funds with lower performance showed a high concentration in the pharmaceutical sector, with the top ten holdings making up 82.19% of the total holdings, indicating a risk in sector concentration [7].